Harpoon Therapeutics, Inc. (NASDAQ:HARP) Position Lessened by Kennedy Capital Management LLC

Kennedy Capital Management LLC lowered its position in Harpoon Therapeutics, Inc. (NASDAQ:HARPFree Report) by 90.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,987 shares of the company’s stock after selling 476,947 shares during the quarter. Kennedy Capital Management LLC owned about 1.37% of Harpoon Therapeutics worth $214,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Delphia USA Inc. bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth $57,000. BNP Paribas Arbitrage SA increased its position in shares of Harpoon Therapeutics by 571.5% in the second quarter. BNP Paribas Arbitrage SA now owns 12,986 shares of the company’s stock worth $25,000 after acquiring an additional 11,052 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $66,000. Two Sigma Investments LP lifted its position in shares of Harpoon Therapeutics by 73.6% in the 3rd quarter. Two Sigma Investments LP now owns 33,361 shares of the company’s stock valued at $32,000 after acquiring an additional 14,149 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in Harpoon Therapeutics in the 1st quarter worth approximately $32,000. Institutional investors and hedge funds own 74.01% of the company’s stock.

Harpoon Therapeutics Trading Up 0.1 %

NASDAQ:HARP opened at $23.01 on Monday. Harpoon Therapeutics, Inc. has a 1 year low of $3.11 and a 1 year high of $23.21. The firm has a 50 day moving average of $21.38 and a 200-day moving average of $12.47.

Analysts Set New Price Targets

HARP has been the topic of several recent analyst reports. Citigroup reissued a “neutral” rating and set a $23.00 target price (up from $13.00) on shares of Harpoon Therapeutics in a research note on Monday, February 26th. Leerink Partnrs lowered Harpoon Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, January 8th. TD Cowen reiterated a “market perform” rating on shares of Harpoon Therapeutics in a report on Tuesday, January 16th. HC Wainwright downgraded shares of Harpoon Therapeutics from a “buy” rating to a “neutral” rating and increased their target price for the stock from $12.00 to $23.00 in a research report on Monday, January 8th. Finally, Oppenheimer initiated coverage on shares of Harpoon Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $23.00 price target on the stock. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Harpoon Therapeutics presently has a consensus rating of “Hold” and an average price target of $27.25.

Read Our Latest Stock Analysis on HARP

Harpoon Therapeutics Company Profile

(Free Report)

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.

Read More

Want to see what other hedge funds are holding HARP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harpoon Therapeutics, Inc. (NASDAQ:HARPFree Report).

Institutional Ownership by Quarter for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.